

HETEROCYCLES, Vol. 90, No. 2, 2015, pp. 1124 - 1134. © 2015 The Japan Institute of Heterocyclic Chemistry
Received, 10th July, 2014, Accepted, 28th August, 2014, Published online, 11th September, 2014
DOI: 10.3987/COM-14-S(K)83

CHIRAL PRIMARY AMINO AMIDE ALCOHOL ORGANOCATALYST FOR THE ASYMMETRIC MICHAEL ADDITION OF 4-HYDROXYCOUMARIN WITH α,β -UNSATURATED KETONES

Jun Kumagai,^a Yoshihito Kohari,^a Chigusa Seki,^a Koji Uwai,^a Yuko Okuyama,^b Eunsang Kwon,^c and Hiroto Nakano^{*a}

^a Division of Sustainable and Environmental Engineering, Graduate School of Engineering, Muroran Institute of Technology, 27-1 Mizumoto, Muroran 050-8585, Japan, E-mail: catanaka@mmm.muroran-it.ac.jp


^b Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan, E-mail: yoku@tohoku-pharm.ac.jp

^c Research and Analytical Center for Giant Molecules, Graduate School of Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan, E-mail: ekwon@m.tohoku.ac.jp

Abstract – Chiral primary amino amide organocatalysts were designed and synthesized as new organocatalysts for the enantioselective Michael addition of 4-hydroxycoumarin with α,β -unsaturated ketones to produce chiral warfarin (up to 56% ee with up to 92% yield).

INTRODUCTION

Asymmetric organocatalysis has emerged as an important and rapidly growing area of synthetic organic chemistry, and excellent covalent and non-covalent organocatalysts have been developed for use in a wide range of reactions.¹ The asymmetric Michael addition is one of the most important and efficient




Scheme 1. Catalytic asymmetric synthesis of chiral warfarin

* Dedicated to Prof. Dr. Isao Kuwajima on the occasion of his 77th birthday

methods for C–C bond formation in organic synthesis,² and the reaction of 4-hydroxycoumarin **1** with an α,β -unsaturated ketone, benzylideneacetone **2**, using an organocatalyst is a straightforward method to access chiral warfarin **3** which is an effective and relatively safe agent for preventing thrombosis and embolism.³ Although several efficient organocatalyst⁴ for this reaction have been developed by several groups in recent years, it is difficult to obtain chiral warfarins with satisfactory high enantioselectivity. Therefore, it is still desirable and challenging to develop an effective catalytic system for this conversion. Chiral amine-based molecules, especially primary amine organocatalysts shows efficient asymmetric catalytic activity in this procedure. We designed a series of chiral primary amino amide alcohols **7a-n** with one covalent site and two non-covalent sites in the molecule as an organocatalyst (Scheme 2). The reaction using these designed amino amide alcohol catalyst might proceed through the transition state **X** which is figured in Scheme 2. Since 4-hydroxycoumarins are fixed by the hydrogen bonding interactions with both the hydroxy group and the amide group on the imine intermediate, the coumarins might attack the less sterically crowded face of olefin part on the imine intermediate rather than the sterically crowded face that is masked by the combination of the bulky diphenyl group and the two substituents (R^1 and R^2) at the α and β positions on the imine intermediate.


We describe herein the catalytic ability of the newly designed primary amino amide alcohol organocatalyst for the asymmetric Michael addition of 4-hydroxycoumarins with α,β -unsaturated ketones affording chiral warfarins.



Scheme 2. Concept of catalyst design

RESULTS AND DISCUSSION

Catalysts **7a-o** bearing two substituents, aliphatic and/or aromatic group, at the α and β positions in the molecule were easily prepared by the condensation of *N*-Cbz-amino acids **4** with the corresponding amino alcohols **5a** or amino silyl ether **5b** in the presence of stoichiometric amounts of HOBT and EDC followed by the debenzoyloxycarbonylation of the *N*-Cbz amino amide alcohols **6a-o** using H_2 and Pd-C (5%) at up to 98% yields, respectively (Scheme 3). We first examined the Michael addition of common




Scheme 3. Preparations of amino amide alcohol organocatalysts

4-hydroxycoumarin **1** with benzylideneacetone **2** using the obtained amino amide alcohols **7a-n** as organocatalysts (Table 1). The reaction of **1** (1 equiv) with **2** (1.2 equiv) was carried out at room temperature in THF (8 equiv) in the presence of 20 mol% of catalysts **7a-n** and 20 mol% of additives to afford the chiral warfarin **3**, respectively (entries 1-14). As a result of these reactions, all catalysts showed a catalytic activity and afforded warfarin **3** in moderate to fairly good chemical yields (56-91%, entries 1-14). However, satisfactory enantioselectivity was not observed under these reaction conditions. The best enantioselectivity was 43 % ee with 85% yield in the case of using the catalyst **7l** which was bearing two *iso*-butyl moieties at α and β positions on the molecule (entry 12). The use of stereoisomer **7n** (α : [*S*], β : [*R*]) of catalyst **7l** (α : [*S*], β : [*S*]) caused a drop in the enantioselectivity (31% ee, entry 14), although the highest chemical yield (91%) was observed. The same reaction using amino amide silyl ether catalyst **7o** in which the hydroxyl group was protected by a trimethylsilyloxy (TMS) group brought about a great decrease in the chemical yield and enantioselectivity (65%, 15% ee, entry 15) in comparison with those of the corresponding amino amide alcohol catalyst **7l** with free hydroxy group (86%, 43% ee, entry 15). This difference may be due to the loss of the ability for hydrogen bonding to 4-hydroxycoumarin **1** or the steric influence of the bulkier trimethylsilyloxy group on the molecule, although the reasons are not clear. To further improve the enantioselectivity, the reactions using **7l** were examined at lower temperatures of both 0 °C and -30 °C (entries 17 and 18). However, satisfactory results were not observed under each temperatures for enantioselectivity and chemical yield. Next, to optimize the reaction conditions using the best catalyst **7l**, we examined the effect of reducing the molar ratio of **7l**. However, the decrease of catalytic loading of **7l** to 10 mol% resulted in a substantial decrease in the chemical yield (46%) with a slight decrease in enantioselectivity (33% ee, entry 16). Furthermore, the effects of additives such as CF₃CO₂H, CCl₃CO₂H, and hexafluoroisopropyl alcohol (HFIP) in this reaction were investigated, respectively (entries 19-21). An additive has generally used for the

improvement of the chemical yield and enantioselectivity in the Michael reaction for warfarin.^{4b,c,f,g,i,j,m} Unfortunately, these additives did not work more effectively than MeCO₂H and the chemical yields were significantly decreased under these reaction conditions. We examined the reactions of **1** (1 equiv) with **2** (1.2 equiv) carried out at room temperature in THF (8 equiv) in the presence of 20 mol% of catalyst **7l** without any additive (entries 22-24). An increase in enantioselectivity was observed with good chemical yield (53%, 50% ee, entry 22). Furthermore, extending the reaction time from 24 to 72 h led to a great increase in the chemical yield (86%) with 52% ee (entry 26). After **7l** was identified as effective

Table 1. The effect of the catalyst in the Michael addition




entry	catalyst (mol%)	additive	solvent	temp (°C)	time (h)	yield (%) ^a	ee (%) ^b
1	7a (20)	MeCO ₂ H	THF	rt	24	67	43
2	7b (//)	//	//	//	//	77	19
3	7c (//)	//	//	//	//	73	24
4	7d (//)	//	//	//	//	74	42
5	7e (//)	//	//	//	//	76	17
6	7f (//)	//	//	//	//	75	24
7	7g (//)	//	//	//	//	67	13
8	7h (//)	//	//	//	//	56	17
9	7i (//)	//	//	//	//	84	10
10	7j (//)	//	//	//	//	67	41
11	7k (//)	//	//	//	//	85	42
12	7l (//)	//	//	//	//	86	43
13	7m (//)	//	//	//	//	78	26
14	7n (//)	//	//	//	//	91	31
15	7o (//)	//	//	//	//	65	-15
16	7l (10)	//	//	//	//	46	33
17	7l (20)	//	//	0	//	32	41
18	7l (//)	//	//	-30	//	15	40
19	7l (//)	CF ₃ CO ₂ H	//	rt	//	24	32
20	7l (//)	CCl ₃ CO ₂ H	//	//	//	22	30
21	7l (//)	HFIP ^c	//	//	//	35	20
22	7l (//)	-	//	//	//	53	50
23	7l (//)	-	//	//	48	65	51
24	7l (//)	-	//	//	72	86	52
25	7l (//)	-	Et ₂ O	//	//	92	37
26	7l (//)	-	CH ₂ Cl ₂	//	//	64	25
27	7l (//)	-	MeCN	//	//	51	22
38	7l (//)	-	benzene	//	//	75	29
29	7l (//)	-	toluene	//	//	49	34
30	7l (//)	-	EtOH	//	//	51	27
31	7l (//)	-	2-PrOH	//	//	73	27

^a Isolated yield. ^b The ee was determined by chiral HPLC using a Daicel AD-H column (*n*-hexane : 2-propanol = 80 : 20). ^c Hexafluoroisopropyl alcohol.

organocatalyst, we also examined solvent effects on this reaction. Commonly used both aprotic (Et₂O, CH₂Cl₂, MeCN, benzene, toluene) and protic (EtOH, 2-PrOH) solvents were screened, respectively (entries 25-31). Only Et₂O afforded a fairly good chemical yield (92%, entry 25), but other solvents gave chiral warfarin **3** in moderate to good yields (49-75%, entries 26-31). Unfortunately, no improvements in enantioselectivity were obtained when other catalysts **7a-k**, **m-o** were used.

Under the optimized reaction conditions, a wide range of the Michael additions with 4-hydroxycoumarins **1**, **8a-d**⁵ and α,β unsaturated ketones **2**, **9a-h**⁶ were investigated and the results are shown in Table 2. In all the Michael additions, catalyst **71** was performed to afford the corresponding chiral warfarins (up to 87%, up to 56% ee, entries 1-12). In particular, the reaction of **1** with bulkier aromatic 2-naphthylated α,β -unsaturated ketone **9g** afforded the corresponding chiral warfarin **10g** in moderate enantioselectivity and good chemical yield (56%, 56% ee, entry 7).

Table 2. The Michael additions of 4-hydroxycoumarins with enones using catalyst **71**




entry	coumarin 1,8	enone 2,9	R	product 10	yield (%) ^a	ee (%) ^b
1	1	9a	3-F-Ph	10a	65	43
2	1	9b	4-F-Ph	10b	72	50
3	1	9c	2-Cl-Ph	10c	83	3
4	1	9d	3-Cl-Ph	10d	87	41
5	1	9e	4-Cl-Ph	10e	77	52
6	1	9f	1-naph	10f	29	29
7	1	9g	2-naph	10g	56	56
8	1	9h	furyl	10h	32	32
9	8a	2	Ph	10i	84	36
10	8b	2	Ph	10j	77	38
11	8c	2	Ph	10k	66	51
12	8d	2	Ph	10l	70	51

^a Isolated yield. ^b The ee was determined by chiral HPLC using a Daicel AD-H column (*n*-hexane : 2-propanol = 80 : 20).

Based on the observed enantiopurity (52% ee, entry 24, Table 1) of chiral warfarin **3** that was obtained from the reaction of **1** with **2**, a model of the enantioselective reaction under the condition without additives was proposed as follows (Scheme 4). The reaction might be go through the transition state **A** which is fixed by the two hydrogen bonding interactions of the hydroxy group on the imine intermediate and the carbonyl group on the 4-hydroxycoumarin **1** and of the carbonyl group on the imine intermediate and the hydroxy group on **1**. Then 4-hydroxycoumarin might attack the *si*-face of the olefin part on the

imine intermediate rather than the sterically crowded *re*-face that was masked by the combination of the bulky diphenyl group and the two *iso*-butyl groups on the imine intermediate in the transition state **A**.



Scheme 4. Plausible reaction course

In conclusion, new chiral amino amide alcohol organocatalysts **7a-o** were explored. The catalysts were easily prepared from the condensation of cheaply and commercially available chiral amino acids with amino alcohols in two steps. The Michael addition of 4-hydroxycoumarins with α,β -unsaturated ketones using the explored catalyst **7I** provided the corresponding Michael adduct **3** in moderate enantioselectivity (up to 56% ee) and fairly good chemical yield (up to 92%). Further optimizations of the structure of the catalyst **7** to increase enantioselectivity in this reaction are now in progress.

EXPERIMENTAL

IR spectra were measured with a JASCO FT/IR-400 spectrophotometer. $^1\text{H-NMR}$ spectra were recorded on a JEOL JNM-ECA 500 spectrometer with TMS as an internal standard. MS were taken on Hitachi RMG-6MG and JEOL-JNM-DX 303 spectrometers. Optical rotations were measured with JASCO DIP-360 digital polarimeter.

General procedure for the preparations of amino amide alcohol organocatalysts **7a-n**

A solution of *N*-Cbz amino acid **4** (1 mmol) and amino alcohol **5a** (1 mmol) were dissolved in CH_2Cl_2 (10 mL). To the solution, EDC (1.4 mmol) and HOBT (1 mmol) was added and the solution was stirred at 0 °C for 1 h and room temperature for another 20 h. The reaction mixture was quenched with aqueous HCl (0.1 N) and extracted with AcOEt. The combined organic layer was washed with a saturated aqueous NaHCO_3 , brine, dried over anhydrous Na_2SO_4 , and filtered. The filtrate was concentrated under reduced pressure to give the crude product which was used for the next step without further purification. To a solution of crude *N*-Cbz amino amide alcohols **6a-n** in MeOH (10 mL) was added 5 % Pd/C (10 wt%) under hydrogen atmosphere and the mixture stirred at 50 °C for 24 h. The reaction mixture was filtered

and the solvent was evaporated under reduced pressure to give the residue. The residue was purified by column chromatography on silica gel (AcOEt : hexane = 1 : 2) to afford the amino amide alcohol **7a-n**. Compounds **7j-l**⁷ were known compounds and were identified by spectral data which were in good agreement with those reported.

(S)-2-Amino-N-((S)-2-hydroxy-1,2,2-triphenylethyl)-2-phenylacetamide (7a)

White crystal (AcOEt), mp 188-189 °C, $[\alpha]_D^{23}$ -27.3 (c 0.21, CHCl₃). IR (neat) cm⁻¹: 3304, 3058, 3029, 1636. ¹H-NMR (CDCl₃) δ: 7.55-6.93 (m, 20H), 6.01-5.98 (m, 1H), 4.37-4.36 (d, 1H, *J* = 6.6). ¹³C-NMR (CDCl₃) δ: 172.2, 144.2, 137.4, 128.8, 128.6, 128.5, 128.4, 128.1, 127.9, 127.8, 127.5, 127.2, 127.0, 126.9, 126.0, 125.6, 80.9, 77.3, 77.1, 76.8, 59.9, 21.1, 14.2. Ms *m/z*: 422. HRMS (EI) calcd for (C₂₈H₂₆N₂O₂): 422.1994, Found: 422.1994. Anal. Calcd for (C₂₈H₂₆N₂O₂): C 79.59, H 6.20, N 6.63, O 7.57, Found: C 79.48, H 6.33, N 6.60, O 7.46.

(S)-2-Amino-N-((S)-1-hydroxy-3-methyl-1,1-diphenylbutan-2-yl)-2-phenylacetamide (7b)

White crystal (AcOEt), mp 153-154 °C, $[\alpha]_D^{23}$ -24.5 (c 1.02, CHCl₃). IR (neat) cm⁻¹: 3309, 2960, 1644. ¹H-NMR (CDCl₃) δ: 7.48-7.15 (m, 15H), 4.82-4.80 (m, 1H), 4.35 (s, 1H), 0.87-0.58 (m, 6H). ¹³C-NMR (CDCl₃) δ: 129.1, 128.9, 128.6, 128.5, 128.4, 128.2, 128.1, 127.0, 125.3, 125.2, 125.0, 81.9, 77.3, 77.1, 76.8, 67.0, 58.2, 28.8, 22.8, 17.5. Ms *m/z*: 388. HRMS (EI) calcd for (C₂₅H₂₈N₂O₂): 388.2151, Found: 388.2161.

(S)-2-Amino-N-((S)-1-hydroxy-1,1-diphenylpropane-2-yl)-2-phenylacetamide (7c)

White crystal (AcOEt), mp 150-151 °C, $[\alpha]_D^{23}$ -15.0 (c 1.00, CHCl₃). IR (neat) cm⁻¹: 3297, 2942, 1652. ¹H-NMR (CDCl₃) δ: 7.48-7.02 (m, 15H), 4.99-4.93 (m, 1H), 4.31 (s, 1H), 1.16-1.15 (d, 3H, *J* = 6.6 Hz). ¹³C-NMR (CDCl₃) δ: 144.4, 136.2, 128.9, 128.5, 128.3, 128.1, 127.2, 127.0, 125.5, 125.3, 80.3, 77.3, 77.1, 76.8, 67.0, 51.1, 16.1. Ms *m/z*: 360. HRMS (EI) calcd for (C₂₃H₂₄N₂O₂): 360.1838, Found: 360.1837.

(S)-2-Amino-N-((S)-2-hydroxy-1,2,2-triphenylethane)-3-phenylpropanamide (7d)

White crystal (AcOEt), mp 194-195 °C, $[\alpha]_D^{22}$ -201.2 (c 0.83, CHCl₃). IR (neat) cm⁻¹: 3311, 2956, 1644. ¹H-NMR (CDCl₃) δ: 8.29-8.27 (d, 1H, *J* = 8.4 Hz), 7.71-6.01 (m, 20H), 6.03-6.01 (d, 1H, *J* = 9.2 Hz), 3.47-3.41 (m, 1H), 3.04-3.00 (m, 1H), 2.54-2.50 (m, 1H), 1.09 (brs, 2H). ¹³C-NMR (CDCl₃) δ: 173.6, 144.5, 144.4, 137.8, 137.7, 129.3, 128.7, 128.3, 128.1, 127.9, 127.5, 127.2, 127.0, 126.7, 126.1, 125.7, 81.0, 77.3, 77.1, 76.8, 59.1, 56.3, 40.5. Ms *m/z*: 437 [M+H]⁺. HRMS (EI) calcd for (C₂₉H₂₈N₂O₂+H)⁺: 437.2229, Found: 437.2216. Anal. Calcd for (C₂₉H₂₈N₂O₂): C 79.79, H 6.46, N 6.42, O 7.33, Found: C 79.56, H 6.41, N 6.50, O 7.39.

(S)-2-Amino-N-((S)-1-hydroxy-3-methyl-1,1-diphenylbutan-2-yl)-3-phenylpropanamide (7e)

White crystal (AcOEt), mp 165-166 °C, $[\alpha]_D^{21}$ -95.6 (c 0.93, CHCl₃). IR (neat) cm⁻¹: 3313, 2953, 1637. ¹H-NMR (CDCl₃) δ: 7.71-7.69 (d, 1H, *J* = 9.7 Hz), 7.69-7.04 (m, 5H), 4.82-4.80 (m, 1H), 3.43-3.41 (m, 1H), 3.07-3.04 (m, 1H), 2.48-2.39 (m, 1H), 0.89-0.85 (m, 6H). ¹³C-NMR (CDCl₃) δ: 146.6, 145.6, 129.3, 128.8, 128.4, 128.2, 128.0, 126.9, 126.8, 125.6, 125.4, 81.9, 77.3, 77.1, 76.8, 56.6, 40.8, 28.8, 23.0, 18.2. Ms *m/z*: 403 [M+H]⁺. HRMS (EI) calcd for (C₂₆H₃₀N₂O₂+H)⁺: 403.2386, Found: 403.2397.

(S)-2-Amino-N-((S)-1-hydroxy-1,1-diphenylpropane-2-yl)-3-phenylpropanamide (7f)

White crystal (AcOEt), mp 167-168 °C; $[\alpha]_D^{20}$ -85.8 (c 0.99, CHCl₃). IR (neat) cm⁻¹: 3325, 2970, 1644. ¹H-NMR (CDCl₃) δ: 7.60-7.59 (d, 1H, *J* = 8.9 Hz), 7.51-7.09 (m, 15H), 4.99-4.93 (m, 1H), 3.38-3.36 (m, 1H), 3.04-3.00 (m, 1H), 2.38-2.32 (m, 1H), 1.15-1.13 (d, 3H, *J* = 6.6 Hz). ¹³C-NMR (CDCl₃) δ: 174.2, 145.5, 144.9, 137.9, 129.3, 128.7, 128.4, 128.2, 127.0, 126.9, 126.8, 125.8, 125.7, 80.6, 77.3, 77.1, 76.8, 56.3, 51.7, 40.7, 15.8. Ms *m/z*: 375 [M+H]⁺. HRMS (EI) calcd for (C₂₄H₂₆N₂O₂+H)⁺: 375.2073, Found: 375.2072.

(S)-2-Amino-N-((S)-1-hydroxy-1,1,2-triphenylethane)-3,3-dimethylbutanamide (7g)

White crystal (AcOEt), mp 210-211 °C, $[\alpha]_D^{21}$ -215.5 (c 0.90, CHCl₃). IR (neat) cm⁻¹: 3325, 2969, 1645. ¹H-NMR (CDCl₃) δ: 7.75-7.73 (m, 1H), 7.62-6.61 (m, 2H), 7.37-7.06 (m, 13H), 6.09-6.04 (m, 1H), 2.96-2.95 (m, 1H), 0.99 (brs, 2H), 0.81 (s, 9H). ¹³C-NMR (CDCl₃) δ: 172.9, 144.3, 128.8, 128.4, 128.1, 127.9, 127.5, 127.2, 127.1, 125.9, 125.5, 81.0, 77.3, 77.1, 76.8, 64.5, 59.1, 34.1, 26.6. Ms *m/z*: 402. HRMS (EI) calcd for (C₂₆H₃₀N₂O₂): 402.2307, Found: 402.2301.

(S)-2-Amino-N-((S)-1-hydroxy-3-methyl-1,1-diphenylbutan-2-yl)-3,3-dimethylbutanamide (7h)

White crystal (AcOEt), mp 240-241 °C, $[\alpha]_D^{21}$ -70.7 (c 0.41, CHCl₃). IR (neat) cm⁻¹: 3422, 2969, 1647. ¹H-NMR (CDCl₃) δ: 7.55-7.04 (m, 10H), 5.08-5.00 (m, 1H), 2.80 (s, 1H), 0.87 (s, 9H), 0.83 (s, 6H). ¹³C-NMR (CDCl₃) δ: 129.0, 128.2, 128.1, 126.7, 126.4, 126.1, 125.1, 124.7, 77.3, 77.1, 76.8, 65.0, 33.7, 29.9, 26.8. Ms *m/z*: 368. HRMS (EI) calcd for (C₂₃H₃₂N₂O₂): 368.2464, Found: 368.2448.

(S)-2-Amino-N-((S)-1-hydroxy-1,1-diphenylpropane-2-yl)-3,3-dimethylbutanamide (7i)

White crystal (AcOEt), mp 111-112 °C, $[\alpha]_D^{22}$ -39.0 (c 0.87, CHCl₃). IR (neat) cm⁻¹: 3253, 2969, 1652. ¹H-NMR (CDCl₃) δ: 7.52-7.04 (m, 10H), 5.06-5.00 (m, 1H), 2.92 (s, 1H), 1.52 (brs, 2H), 1.15-1.14 (d, 3H, *J* = 6.6 Hz), 0.78 (s, 9H). ¹³C-NMR (CDCl₃) δ: 173.2, 153.3, 145.5, 145.0, 128.5, 128.3, 127.0, 126.9, 125.6, 125.5, 80.5, 77.3, 77.1, 76.8, 64.5, 51.6, 33.8, 26.5, 15.8. Ms *m/z*: 340. HRMS (EI) calcd for (C₂₁H₂₈N₂O₂): 340.2151, Found: 340.2162.

(S)-2-Amino-N-((S)-1-hydroxy-1,1-diphenylpropane-2-yl)-4-methylpentanamide (7m)

White crystal (AcOEt), mp 101-102 °C, $[\alpha]_D^{22}$ -34.6 (c 0.52, CHCl₃). IR (neat) cm⁻¹: 3308, 2969, 1644. ¹H-NMR (CDCl₃) δ: 7.51-7.13 (m, 10H), 4.99-4.92 (m, 1H), 3.16-3.14 (m, 1H), 1.16-1.15 (d, 3H, *J* = 6.6), 0.83-0.79 (m, 6H). ¹³C-NMR (CDCl₃) δ: 175.6, 145.6, 145.0, 128.4, 128.2, 127.0, 126.8, 125.7, 125.6, 80.6, 77.3, 77.1, 76.8, 53.5, 51.8, 43.8, 24.7, 23.3, 21.4, 15.7. Ms *m/z*: 340. HRMS (EI) calcd for (C₂₁H₂₈N₂O₂): 340.2151, Found: 340.2136. Anal. Calcd for (C₂₁H₂₈N₂O₂): C 74.08, H 8.29, N 8.23, O 9.40, Found: C 74.01, H 8.34, N 8.17, O 9.31.

(S)-2-Amino-N-((R)-1-hydroxy-4-methyl-1,1-diphenylpentan-2-yl)-4-methylpentanamide (7n)

White crystal (AcOEt), mp 162-163 °C, $[\alpha]_D^{23}$ -4.5 (c 0.22, CHCl₃). IR (neat) cm⁻¹: 3290, 2969, 1645. ¹H-NMR (CDCl₃) δ: 7.54-7.50 (m, 4H), 7.44-7.7.29 (m, 3H), 7.24-7.11 (m, 3H), 4.94-4.90 (m, 1H), 3.20-3.18 (m, 1H), 0.99-0.79 (m, 12H). ¹³C-NMR (CDCl₃) δ: 175.9, 145.7, 145.1, 128.4, 128.1, 127.0, 126.6, 125.6, 81.3, 77.3, 77.1, 76.8, 54.3, 53.4, 43.6, 38.8, 25.2, 24.7, 24.0, 23.3, 21.6, 21.4. Ms *m/z*: 382. HRMS (EI) calcd for (C₂₄H₃₄N₂O₂): 382.2620, Found: 382.2630.

General procedure for the preparation of amino amide alcohol catalyst 7o

A solution of amino alcohol **5a** (1 mmol) in CH₂Cl₂ (15 mL) was cooled down to -30 °C. To the solution, Et₃N (1.2 mmol) and hexamethyldisilazane (1.2 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. The solution was quenched with water and extracted with CHCl₃. The combined organic layer was washed with a brine, dried over anhydrous Na₂SO₄, and filtrated. The filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography on silica gel (AcOEt : hexane = 1 : 4) to afford (S)-4-methyl-1,1-diphenyl-1-trimethylsilyloxypentan-2-amine **5b**. *N*-Cbz amino acid **4** (1 mmol) and (S)-4-methyl-1,1-diphenyl-1-trimethylsilyloxypentan-2-amine **5b** (1 mmol) were dissolved in CH₂Cl₂ (10 mL) and the solution was cooled down to 0 °C. EDC (1.4 mmol) and HOBT (1 mmol) was added to the solution and the solution was stirred at 0 °C for 1 h and room temperature for another 20 h. The solution was quenched with aqueous HCl (0.1 N) and extracted with AcOEt. The combined organic layer was washed with a saturated aqueous NaHCO₃, brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give the crude product **6o** which was used for the next step without further purification. The solution of **6o** in MeOH (10 mL) was added 5 % Pd/C (10 wt%) under hydrogen atmosphere and the mixture stirred at 50 °C for 24 h. The reaction mixture was filtered and the solvents were evaporated under reduced pressure to give the residue. The crude residue was purified by column chromatography on silica gel (AcOEt : hexane = 1 : 2) to afford the amino amide silyl ether **7o**.

(S)-4-Methyl-1,1-diphenyl-1-trimethylsilyloxypentan-2-amine (5b)

Colorless oil, $[\alpha]_D^{21}$ -63.5 (c 0.21, CHCl₃). IR (neat) cm⁻¹: 1249, 2953. ¹H-NMR (CDCl₃) δ: 7.39-7.23 (m, 10H), 3.76-3.73 (m, 1H), 1.88-1.78 (m, 1H), 1.44-1.38 (m, 1H), 1.01-1.00 (d, 3H, *J* = 6.6 Hz), 0.84-0.82 (d, 3H, *J* = 6.6 Hz), -0.17 (s, 9H). ¹³C-NMR (CDCl₃) δ: 128.7, 128.2, 127.6, 127.5, 127.4, 127.2, 83.5, 50.7, 40.8, 24.5, 24.1, 22.8, 22.1, 21.4, 1.8. Ms *m/z*: 341. HRMS (EI) calcd for (C₂₄H₃₄N₂O₂): 341.2175, Found: 341.2173.

(S)-2-Amino-N-((S)-4-methyl-1,1-diphenyl-1-trimethylsilyloxypentan-2-yl)-4-methylpentanamide (7o)

White crystal (AcOEt), mp 75-76 °C; $[\alpha]_D^{22}$ -83.3 (c 0.24, CHCl₃). IR (neat) cm⁻¹: 2969, 1669. ¹H-NMR (CDCl₃) δ: 7.41-7.20 (m, 10H), 5.09-5.00 (m, 1H), 3.24-3.19 (m, 1H), 1.03-0.72 (m, 12H), -0.12 (s, 9H). ¹³C-NMR (CDCl₃) δ: 174.7, 144.5, 128.8, 128.2, 127.8, 127.5, 127.4, 127.1, 83.8, 77.3, 77.1, 76.8, 53.7, 51.7, 44.3, 41.0, 24.7, 24.3, 23.5, 22.0, 21.4, 1.9, 0.9. Ms *m/z*: 455 [M+H]⁺. HRMS (EI) calcd for (C₂₄H₃₄N₂O₂+H)⁺: 455.3094, Found: 455.3099.

General procedure for the asymmetric Michael reaction of 4-hydroxycoumarines 1, 8a-d to α,β-unsaturated ketones 2, 9a-h

4-Hydroxycoumarines **1**, **8a-d** (0.1 mmol), α,β-unsaturated ketones **2**, **9a-h** (0.12 mmol), amino amide alcohol catalysts **7a-o** (0.02 mmol) with/without additives (0.02 mmol) were stirred in THF (0.8 mL) at room temperature for the times shown in the Table 1. The reaction mixture was directly purified by preparative TLC on silica gel (hexane : AcOEt = 3 : 1) to afford warfarin **3** and its analogs **10a-l**. All adducts were known compounds and were identified by spectral data (¹H and ¹³C-NMR) which were in good agreement with those reported.⁴ The enantiomeric excess (ee) were determined by HPLC (DAICEL CHIRALPAK AD-H, 1.0 mL/min, *n*-hexane : 2-propanol = 80 : 20).⁴

REFERENCES

- (a) B. List, *Synlett.*, 2001, 1675; (b) P. I. Dalko and L. Moisan, *Angew. Chem. Int. Ed.*, 2004, **37**, 580; (c) W. Notz, F. Tanaka, and C. F. Barbas III, *Acc. Chem. Res.*, 2004, **37**, 580; (d) J. Seayad and B. List, *Org. Biomol. Chem.*, 2005, **3**, 719; (e) H. Yang and R. G. Carter, *Synlett*, 2010, 2827.
- (a) J. Christoffers, *Eur. J. Org. Chem.*, 1998, **7**, 1259; (b) 'Comprehensive Asymmetric Catalysis,' Vol. I-III, ed. by E. N. Jacobsen, A. Pfaltz, and H. Yamamoto, Springer, Berlin, 1999; (c) M. P. Sibi and S. Manyem, *Tetrahedron*, 2000, **56**, 8033; (d) N. Krause and A. Hoffmann-Roder, *Synthesis*, 2001, 171; (e) O. M. Berner, L. Tedeschi, and D. Enders, *Eur. J. Org. Chem.*, 2002, 1877; (f) J. Christoffers and A. Baro, *Angew. Chem. Int. Ed.*, 2003, **42**, 1688; (g) R. Ballini, G. Bosica, D. Fiorini,

- A. Palmieri, and M. Petrini, [Chem. Rev., 2005, 105, 933](#); (h) L. W. Xu and C. G. Xia, [Eur. J. Org. Chem., 2005, 633](#); (i) D. Almasi, D. A. Alonso, and C. Najera, [Tetrahedron: Asymmetry, 2007, 18, 299](#); (j) J. L. Vicario, D. Badia, and L. Carrillo, [Synthesis, 2007, 2065](#); (k) S. Sulzer-Mossé and A. Alexakis, [Chem. Commun., 2007, 3123](#); (l) S. B. Tsogoeva, [Eur. J. Org. Chem., 2007, 1701](#); (m) C. F. Nising and S. Bräse, [Chem. Soc. Rev., 2008, 37, 1218](#); (n) P. M. Liu, C. Chang, R. J. Reddy, Y. F. Ting, H. H. Kuan, and K. Chen, [Eur. J. Org. Chem., 2010, 42](#).
3. (a) R. A. O'Railly, [N. Engl. J. Med., 1976, 295, 354](#); (b) L. B. Wingard, R. A. O'Railly, and G. Levy, *Clin. Pharmacol. Ther.*, 1978, **23**, 212; (c) H. P. Rang, M. M. Dale, J. M. Ritter, and P. Gardner, *Pharmacology 4th ed.*, Churchill Livingstone, Philadelphia, 2001.
4. (a) N. Halland, T. Hansen, and K. A. Jørgensen, [Angew. Chem. Int. Ed., 2003, 42, 4955](#); (b) H. Kim, C. Yen, P. Preston, and J. Chin, [Org. Lett., 2006, 8, 5239](#); (c) J. W. Xie, L. Yue, W. Chen, W. Du, J. Zhu, J. G. Deng, and Y. C. Chen, [Org. Lett., 2007, 9, 413](#); (d) Z. H. Dong, L. J. Wang, X. H. Chen, X. H. Liu, L. L. Lin, and X. M. Feng, [Eur. J. Org. Chem., 2009, 5192](#); (e) T. E. Kristensen, K. Vestli, F. K. Hansen, and T. Hansen, [Eur. J. Org. Chem., 2009, 5185](#); (f) H. M. Yang, L. Li, K. Z. Jiang, J. X. Jiang, G. Q. Lai, and L. W. Xu, [Tetrahedron, 2010, 66, 9708](#); (g) H. M. Yang, Y. H. Gao, L. Li, Z. Y. Jiang, G. Q. Lai, C. G. Xia, and L. W. Xu, [Tetrahedron Lett., 2010, 51, 3836](#); (h) R. Q. Mei, X. Y. Xu, Y. C. Li, J. Y. Fu, Q. C. Huang, and L. X. Wang, [Tetrahedron Lett., 2011, 14, 1566](#); (i) J. Dong and D. M. Du, [Org. Biomol. Chem., 2012, 10, 8125](#); (j) Y. J. Lim and D. Y. Kim, [Bull. Korean Chem. Soc., 2012, 33, 1825](#); (k) S. K. Ray, P. K. Singh, N. Molleti, and V. K. Singh, [J. Org. Chem., 2012, 77, 8802](#); (l) T. Shi, Z. Guo, H. Yu, J. Xie, Y. Zhong, and W. Zhu, [Adv. Synth. Catal., 2013, 355, 2538](#); (m) M. Rogozińska-Szymczak and J. Mlynarski, [Tetrahedron: Asymmetry, 2014, 25, 813](#).
5. (a) P. R. Kym, R. Iyengar, A. J. Souers, J. K. Lynch, A. S. Judd, J. Gao, J. Freeman, M. Mulhern, G. Zhao, A. Vasudevan, D. Wodka, C. Blackburn, J. Brown, J. L. Che, C. Cullis, S. J. Lai, M. J. LaMarche, T. Marsilje, J. Roses, T. Sells, B. Geddes, E. Govek, M. Patane, D. Fry, B. D. Dayton, S. Brodjian, D. Falls, M. Brune, E. Bush, R. Shapiro, V. Knourek-Segel, T. Fey, C. McDowell, G. A. Reinhart, L. C. Preusser, K. Marsh, L. Hernandez, H. L. Sham, and C. A. Collins, [J. Med. Chem., 2005, 48, 5888](#); (b) K. A. Nolan, J. R. Doncaster, M. S. Dunstan, K. A. Scott, A. D. Frenkel, D. Siegel, D. Ross, J. Barnes, C. Levy, R. C. Whitehead, I. J. Stratford, and R. A. Bryce, [J. Med. Chem., 2009, 52, 7142](#).
6. X. Li, L. Li, Y. Tang, L. Zhong, L. Cun, J. Zhu, J. Liao, and J. Deng, [J. Org. Chem., 2010, 75, 2981](#).
7. (a) X. Y. Xu, Y. Z. Wang, and L. Z. Gong, [Org. Lett., 2007, 9, 4247](#); (b) C. S. Da, L. P. Che, Q. P. Guo, F. C. Wu, X. Ma, and Y. N. Jia, [J. Org. Chem., 2009, 74, 2541](#).